FLGT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FLGT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some short-term momentum, but the setup is too extended and the fundamental/Wall Street backdrop is not strong enough to support an immediate long-term buy. I would wait for a better entry rather than chase it after the recent move.
The trend is short-term bullish: MACD histogram is positive and expanding, and the price closed above the previous close at 17.52. However, RSI_6 is 80.932, which is strongly overbought, suggesting the move is already stretched. Moving averages are converging, which often signals indecision or a possible transition phase rather than a clean long-term uptrend. Price is currently near resistance at 17.668 (R2), with support at 17.087 (R1) and 16.147 pivot. The technical picture supports momentum, but not an attractive fresh entry for a beginner investor seeking long-term durability.
["Strong bullish options sentiment with very low put-call ratios", "Positive short-term price momentum and expanding MACD histogram", "Price recently moved above the prior close and is holding near resistance", "No negative news flow in the last week"]
["RSI is overbought, making the stock extended after the recent move", "Hedge funds have been selling, with selling up 169.46% over the last quarter", "Analyst price targets have been cut recently, including Piper Sandler cutting target to $15 from $30 and UBS cutting to $22 from $35", "No recent news catalyst to justify a fresh long-term entry", "No significant insider buying and no recent congress trading data"]
No financial snapshot data was available, so a quarter-by-quarter revenue or earnings assessment cannot be made from the provided data. The latest quarter season is not specified in the dataset. Based on the lack of financial detail, there is no evidence here to support a strong fundamental long-term buy case.
Analyst sentiment has weakened recently. Piper Sandler lowered its price target to $15 from $30 and kept a Neutral rating after quarterly results, while UBS also cut its target to $22 from $35 though it maintained a Buy rating. This shows falling expectations from Wall Street overall. The pro view is that some analysts still see upside potential, but the con view is stronger right now because target cuts suggest confidence has deteriorated.
